Sonnet BioTherapeutics completes safety review for combination therapy in sarcoma treatment
From GlobeNewswire: 2025-03-26 09:05:00
SON-1010 is being studied in combination with trabectedin for advanced soft tissue sarcoma, showing potential for immune mechanism synergies and improved progression-free survival. The Safety Review Committee found no unexpected toxicities in early dosing of SON-1010, paving the way for full enrollment of up to 18 patients. Annual review showed extended safety of SON-1010 monotherapy with clinical benefit in 83% of patients at the maximum tolerated dose. This combination therapy has the potential to improve upon the $2.1B global market opportunity for trabectedin and address significant unmet medical needs in sarcoma treatment. Management released findings in a “What This Means” segment.
SON-1010, a proprietary version of recombinant human interleukin-12, is being evaluated in combination with trabectedin for adult patients with advanced leiomyosarcoma or liposarcoma. Safety review showed no unexpected toxicities in early dosing, with full enrollment expected for up to 18 patients. The combination therapy aims to improve outcomes in sarcoma treatment by potentially enhancing the therapeutic effectiveness of trabectedin. The goal is to assess combination therapy in earlier-stage patients with soft tissue sarcomas, potentially turning ‘cold’ tumors ‘hot’ and improving treatment responses. The global market opportunity for trabectedin is $2.1B, highlighting the need for improved treatments in sarcoma.
Read more at GlobeNewswire: Sonnet BioTherapeutics Successfully Completes First Safety